Skip navigation

Actavis posts 2Q loss on restructuring charge

The drugmaker Actavis Inc. said Thursday it took a loss in the second quarter on a large restructuring charge related to an acquisition. Full story

Actavis to launch generic epilepsy/bipolar drug

Drugmaker Actavis Inc. said Monday it's received U.S. approval to sell a generic version of Lamictal, a tablet for treating epilepsy and bipolar disorder. Full story

Warner Chilcott markets $4.4 billion deal

NEW YORK (Reuters) - Specialty pharmaceutical Warner Chilcott Plc <WCRX.O> is in market with $4.4 billion in credit facilities that will refinance and combine debt following the company's acquisition by drug manufacturer Actavis Inc <ACT.N>, sources told Thomson Reuters LPC. Full story

Actavis to buy Warner Chilcott in $8.5 billion deal

(Reuters) - Generic drugmaker Actavis Inc <ACT.N> will buy specialty pharmaceuticals company Warner Chilcott Plc <WCRX.O> in a stock deal valued at about $8.5 billion. Full story

Actavis rejected $15 billion offer from Mylan: source

NEW YORK (Reuters) - Actavis Inc <ACT.N> received and rejected a takeover offer from Mylan Inc <MYL.O> last week that valued the generic drugmaker at more than $15 billion, a person familiar with the situation told Reuters on Tuesday. Full story

Actavis says in merger talks with Warner Chilcott

(Reuters) - Generic drugmaker Actavis Inc, formerly Watson Pharmaceuticals, said on Friday that it was in early stage discussions to buy specialty pharmaceutical company Warner Chilcott Plc. Full story

Sponsored Links

Articles

Deal maker Valeant reaches for biggest prize yet

Valeant in talks to buy Actavis for over $13 billion: WSJ

advertisement | ad info